Cleveland Diagnostics

Guiding the Next Step After an Elevated PSA

When a patient presents with elevated PSA, how should a clinician proceed?

For men over 50 years of age with elevated PSA, the IsoPSA Test can support improved risk stratification for clinically significant prostate cancer (csPCa).¹

Learn More

An extensive body of published research has demonstrated the test’s ability to reduce over-detection and over-treatment¹ and predict risk for csPCa over time.²

The test offers simple patient selection with limited exclusion criteria: only a blood sample is needed, and no additional patient information is required. Results are not affected by BPH medications.¹

Visit IsoPSA.com to discover how this test can help better identify patients who may benefit from a biopsy.

PSA on PSA: Supporting Prostate Cancer Awareness in September

This month, Cleveland Diagnostics, developer of the IsoPSA Test, has relaunched the PSA on PSA Campaign for Prostate Cancer Awareness Month.

Short for a Public Service Announcement on the Prostate-Specific Antigen (PSA) test, the national campaign raises awareness of prostate cancer risk and encourages informed conversations about screening and testing.

This year’s campaign will introduce On Call for Men’s Health: A PSA on PSA, a limited video series featuring candid conversations with leaders in urology, prostate cancer, and men’s health.

September | Prostate Cancer Awareness Month.

New episodes will be released weekly throughout September covering topics that shape men’s health outside the exam room, including fear, access to care, mental health, and more.

Visit PSAonPSA.com to learn more and to support prostate cancer awareness this September.

Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9 408.e18.
Abdallah, et al., Urology. 2025 Jan15:S0090 4295(25)00031-7.

This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).